Evan G. Smith

Boston
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA
 
 

Evan Smith is a partner in the Boston office of Latham & Watkins. He represents clients on a broad range of corporate matters in life sciences, technology, and other industry sectors.

He focuses his practice on:

  • Early-stage company formation and strategy
  • Angel and venture capital financings
  • Mergers and acquisitions
  • Public offerings of securities
  • Licensing and other commercial/strategic transactions
  • Employment matters
  • Securities law compliance

Mr. Smith advises entrepreneurs heading startups and other emerging companies in various stages of growth. He also represents more mature companies in strategic investments, acquisitions, and commercial collaborations.

Mr. Smith has been recognized by The Legal 500 as a Leading Lawyer for Venture Capital and Emerging Companies.

In addition to his client work, Mr. Smith has served as Corporate Department Chair in Latham’s Boston office and has managed the office’s attorney training and career development and paralegal programs. Mr. Smith also served on the editing team for the production of Latham's Emerging Companies Book of Jargon. He is also actively involved in several charitable and church-related activities.

In addition to providing day-to-day corporate advice to many companies, transactions on which Mr. Smith has advised clients include:
  • Venture capital financing for Immuneering Corporation 
  • The sale of Ipswitch to Progress
  • The sale of A123 Systems to Wanxiang America and Navitas Systems
  • Venture capital financings for Blockchain (www.blockchain.com)
  • Strategic investments by Boston Scientific in numerous private companies
  • The sale of Cartera Commerce to Ebates (Rakuten)
  • Venture capital financings for and sale of Copiun to Good Technology
  • The formation of and venture capital financings for Drizly
  • Venture capital financings and reverse merger for Epirus Biopharmaceuticals
  • The initial public offering of EverQuote
  • Venture capital financings for Fractyl Laboratories
  • Financings for and sale of Immuneering to Teva Pharmaceutical
  • The sale of Revelops (Logentries) to Rapid7
  • The sale of Micronetics to Mercury Computer Systems
  • The sale of Network Engines to UNICOM Systems
  • Venture financings and initial public offering for Radius Health
  • The formation of and financing rounds for Sungage Financial
  • Venture capital financings for Synack
  • Venture capital financings for TravelPerk
  • Initial public offering and takedown offerings for T2 Biosystems
  • The sale of Twitch to Amazon
  • The sale of Topera to Abbott Laboratories
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.